The DOI matches its Crossref record; 882 of the 882 references it cites were found in a registry or an index.
Cold and hot tumors: from molecular mechanisms to targeted therapy
Open accessAbstract
Immunotherapy has made significant strides in cancer treatment, particularly through immune checkpoint blockade (ICB), which has shown notable clinical benefits across various tumor types. Despite the transformative impact of ICB treatment in cancer therapy, only a minority of patients exhibit a positive response to it. In patients with solid tumors, those who respond well to ICB treatment typically demonstrate an active immune profile referred to as the “hot” (immune-inflamed) phenotype. On the other hand, non-responsive patients may exhibit a distinct “cold” (immune-desert) phenotype, differing from the features of “hot” tumors. Additionally, there is a more nuanced “excluded” immune phenotype, positioned between the “cold” and “hot” categories, known as the immune “excluded” type. Effective differentiation between “cold” and “hot” tumors, and understanding tumor intrinsic factors, immune characteristics, TME, and external factors are critical for predicting tumor response and treatment results. It is widely accepted that ICB therapy exerts a more profound effect on “hot” tumors, with limited efficacy against “cold” or “altered” tumors, necessitating combinations with other therapeutic modalities to enhance immune cell infiltration into tumor tissue and convert “cold” or “altered” tumors into “hot” ones. Therefore, aligning with the traits of “cold” and “hot” tumors, this review systematically delineates the respective immune characteristics, influencing factors, and extensively discusses varied treatment approaches and drug targets based on “cold” and “hot” tumors to assess clinical efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 801–882 of 882
Rouanne, M., Adam, J., Radulescu, C., Letourneur, D., Bredel, D., Mouraud, S., Goubet, A.-G., Leduc, M., Chen, N., Tan, T. Z., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci145666 · Cited by 48
Fu, Y., Li, J., Cai, W., Huang, Y., Liu, X., Ma, Z., Tang, Z., Bian, X., Zheng, J., Jiang, J., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.018 · Cited by 48
Co-stimulatory agonists: An insight into the immunotherapy of cancer
Pourakbari, R., Hajizadeh, F., Parhizkar, F., Aghebati-Maleki, A., Mansouri, S., & Maleki, L. A. (2021) · EXCLI journal · doi:10.17179/excli2021-3522 · Cited by 47
Reiners, K. S., Daßler, J., Coch, C., & von Strandmann, E. P. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00091 · Cited by 45
CD137 (4-1BB) Costimulation Modifies DNA Methylation in CD8+ T Cell–Relevant Genes
Aznar, M. A., Labiano, S., Díaz‐Lagares, Á., Molina, C., Garasa, S., Azpilikueta, A., Etxeberría, I., Sánchez-Paulete, A. R., Korman, A. J., Esteller, M., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0159 · Cited by 44
Wang, R. Y., Gao, C., Raymond, M. B., Dito, G., Kabbabe, D., Shao, X., Hilt, E., Sun, Y. S., Pak, I., Gutierrez, M. E., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0526 · Cited by 43
Advances in Epigenetic Cancer Therapeutics
Hillyar, C., Rallis, K. S., & Varghese, J. S. (2020) · Cureus · doi:10.7759/cureus.11725 · Cited by 43
Zhang, Y., Hughes, K. R., Raghani, R. M., Ma, J. A., Orbach, S. M., Jeruss, J. S., & Shea, L. D. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120666 · Cited by 43
Epigenetic regulation and therapeutic targets in the tumor microenvironment
Xie, Z., Zhou, Z., Yang, S., Zhang, S., & Shao, B. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00126-2 · Cited by 42
Nakamura, S., Ohuchida, K., Hayashi, M., Katayama, N., Tsutsumi, C., Yamada, Y., Hisano, K., Okuda, S., Ohtsubo, Y., Iwamoto, C., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02396-7 · Cited by 42
Qin, S., Xie, B., Wang, Q., Yang, R., Sun, J., Hu, C., Liu, S., Tao, Y., & Xiao, D. (2024) · MedComm · doi:10.1002/mco2.551 · Cited by 42
Combination of attenuated Salmonella carrying PD‐1 siRNA with nifuroxazide for colon cancer therapy
Zhao, T., Feng, Y., Guo, M., Zhang, C., Wu, Q., Chen, J., Guo, S. J., Liu, S., Zhou, Q., Wang, Z., et al. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29432 · Cited by 41
Li, Y., Han, M., Wei, H., Huang, W., Chen, Z., Zhang, T., Qian, M., Lin, J., Nan, G., Sun, X., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01118-6 · Cited by 41
Crombé, A., Dugage, M. R., & Italiano, A. (2022) · 癌症:英文版 · doi:10.1002/cac2.12373 · Cited by 40
Metzger, P., Kirchleitner, S. V., Kluge, M., König, L. M., Hörth, C., Rambuscheck, C. A., Böhmer, D., Ahlfeld, J., Kobold, S., Friedel, C. C., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0778-7 · Cited by 39
Pierini, S., Mishra, A., Perales-Linares, R. F., Uribe‐Herranz, M., Beghi, S., Giglio, A., Pustylnikov, S., Costabile, F., Rafail, S., Amici, A. R. D., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001636 · Cited by 39
The role of anti‐flavivirus humoral immune response in protection and pathogenesis
Hurtado-Monzón, A. M., Cordero‐Rivera, C. D., Farfán-Morales, C. N., Osuna‐Ramos, J. F., Jesús‐González, L. A. D., Reyes-Ruíz, J. M., & del Ángel, R. M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2100 · Cited by 38
Vathiotis, I. A., Moutafi, M. K., Divakar, P., Aung, T. N., Qing, T., Fernandez, A., Yaghoobi, V., El-Abed, S., Wang, Y., Guillaume, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2103 · Cited by 38
Immune Cell Migration to Cancer
Ryan, A. T., Kim, M., & Lim, K. (2024) · Cells · doi:10.3390/cells13100844 · Cited by 38
The Tumor Stroma of Squamous Cell Carcinoma: A Complex Environment That Fuels Cancer Progression
Buruiană, A., Gheban, B., Gheban-Roşca, I. A., Georgiu, C., Crișan, D., & Crişan, M. (2024) · Cancers · doi:10.3390/cancers16091727 · Cited by 37
Hall, P. E., Ready, N., Johnston, A. L., Bomalaski, J. S., Venhaus, R. R., Sheaff, M. T., Krug, L. M., & Szlosarek, P. W. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.07.012 · Cited by 36
Therapeutic Vaccines for Cancer Immunotherapy
Wang, J., Mamuti, M., & Wang, H. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01201 · Cited by 36
Interplay of cGAS with chromatin
Wischnewski, M., & Ablasser, A. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2021.05.011 · Cited by 36
Jacobson, M. E., Becker, K. W., Palmer, C. R., Pastora, L. E., Fletcher, R. B., Collins, K. A., Fedorova, O., Duvall, C. L., Pyle, A. M., & Wilson, J. T. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00568 · Cited by 35
Zhou, J., Zhang, A., & Liang, F. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s254985 · Cited by 34
Becicka, W. M., Bielecki, P. A., Lorkowski, M. E., Moon, T. J., Zhang, Y., Atukorale, P. U., Covarrubias, G., & Karathanasis, E. (2021) · Nanoscale Advances · doi:10.1039/d1na00308a · Cited by 34
Immunosurveillance encounters cancer metabolism
Chuang, Y., Tzeng, S., Ho, P., & Tsai, C. (2024) · EMBO Reports · doi:10.1038/s44319-023-00038-w · Cited by 34
al-Ramadi, B. K., Adeghate, E. A., Mustafa, N., Ponery, A. S., & Fernández-Cabezudo, M. J. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00020-2 · Cited by 33
Datta, J., Xu, S., Rosemblit, C., Smith, J. B., Cintolo, J. A., Powell, D. J., & Czerniecki, B. J. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0208 · Cited by 33
Antimetastatic defense by CD8+ T cells
de Lara, P. T., Castañón, H., Sterpi, M., & van den Broek, M. F. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.10.006 · Cited by 33
T and NK cell abundance defines two distinct subgroups of renal cell carcinoma
Lee, M. H., Järvinen, P., Nísen, H., Brück, O. E., Ilander, M., Uski, I., Theodoropoulos, J., Kankainen, M., Mirtti, T. K., Mustjoki, S. M., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2021.1993042 · Cited by 33
Alessi, J. V., Ricciuti, B., Wang, X., Pecci, F., Federico, A. D., Lamberti, G., Elkrief, A., Rodig, S. J., Lebow, E. S., Eicholz, J. E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39874-8 · Cited by 33
Zhao, Z., Ding, H., Lin, Z.-B., Qiu, S., Yi-ran, Z., Guo, Y., Chu, X., Sam, L. I., Pan, J., & Pan, Y.-L. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.56347 · Cited by 32
Wang, Z., Chen, H., Wang, P., Zhou, M., Li, G., Hu, Z., Hu, Q., Zhao, J., Liu, X., Wu, L., et al. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szab031 · Cited by 32
Intratumoral microbiota: new frontiers in tumor immunity
Zhang, Z., Liao, Y., & Tang, D. (2022) · Carcinogenesis · doi:10.1093/carcin/bgac063 · Cited by 32
Recent advances in the activation and regulation of the cGAS-STING pathway
Fang, R., Jiang, Q., Yu, X., Zhao, Z., & Jiang, Z. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.09.003 · Cited by 32
Does Mycoplasma sp. play role in small cell lung cancer?
Pehlıvan, M., Itırlı, G., Önay, H., Bulut, H., Koyuncuoğlu, M., & Pehlıvan, S. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.01.007 · Cited by 31
Immunotherapeutic Targeting of Tumor-Associated Blood Vessels
Fabian, K. P., & Storkus, W. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_13 · Cited by 30
Modifying Dendritic Cell Activation with Plasmonic Nano Vectors
Vang, K. B., Safina, I., Darrigues, E., Nedosekin, D. A., Nima, Z. A., Majeed, W., Watanabe, F., Kannarpady, G. K., Kore, R. A., Casciano, D. A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04459-1 · Cited by 29
Xu, L., Xu, W., Wen, Z., & Xiong, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020282 · Cited by 28
Pal, S. K., McDermott, D. F., Atkins, M. B., Escudier, B. J., Rini, B. I., Motzer, R. J., Fong, L. H., Joseph, R. W., Oudard, S. M., Ravaud, A., et al. (2020) · British Journal of Urology · doi:10.1111/bju.15058 · Cited by 28
Atypical chemokine receptors in cancer
Samus, M., & Rot, A. (2024) · Cytokine · doi:10.1016/j.cyto.2024.156504 · Cited by 28
Jennewein, L., Bartsch, G., Gust, K., Kvasnicka, H., Haferkamp, A., Blaheta, R., Mittelbronn, M., Harter, P., & Mani, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.8597 · Cited by 27
Mueller, T., Freystein, J., Lucas, H., & Schmoll, H. (2019) · Molecules · doi:10.3390/molecules24162865 · Cited by 27
Dysbacteriosis induces abnormal neurogenesis via LPS in a pathway requiring NF-κB/IL-6
Long, D., Liu, M., Li, H., Song, J., Jiang, X., Wang, G., & Yang, X. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105543 · Cited by 27
Vogt, T. J., Gevensleben, H., Dietrich, J., Kristiansen, G., Bootz, F., Landsberg, J., Goltz, D., & Dietrich, D. (2018) · Oncoimmunology · doi:10.1080/2162402x.2018.1452579 · Cited by 26
Bagaria, S. P., Gatalica, Z., Maney, T., Serie, D., Parasramka, M. A., Attia, S., Krishna, M., & Joseph, R. W. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00071 · Cited by 26
Cordova, A., Ritchie, C., Böhnert, V., & Li, L.-Y. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00440 · Cited by 26
Short-chain fatty acid-releasing nano-prodrugs for attenuating growth and metastasis of melanoma
Shashni, B., & Nagasaki, Y. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.01.054 · Cited by 26
Wang, X., Lu, L., Hong, X., Wu, L., Yang, C., Wang, Y., Li, W., Yang, Y., Cao, D., Di, W. J., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113712 · Cited by 26
Xu, R., Zhao, X., Zhao, Y., Chen, B., Sun, L., Xu, C., Shen, B., Wang, M., Xu, W., & Zhu, W. (2017) · Cell Proliferation · doi:10.1111/cpr.12399 · Cited by 25
Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
Simon, S., Vignard, V., Varey, É., Parrot, T., Knol, A., Khammari, A., Gervois, N., Lang, F., Dréno, B., & Labarrière, N. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1856 · Cited by 25
Ильдарович, Т. А., Dzharullaeva, A. S., Erokhova, A. S., Zemskaya, A., Balyasin, M. V., Ozharovskaia, T. A., Zubkova, O. V., Shevlyagina, N. V., Zhukhovitsky, V. G., Тимофеевна, Ф. И., et al. (2020) · Vaccines · doi:10.3390/vaccines8030519 · Cited by 25
He, R., Li, D., Liu, B., Rao, J., Meng, H., Lin, W., Fan, T. T., Hao, B., Zhang, L., Lu, Z., et al. (2020) · Journal of Cancer · doi:10.7150/jca.50439 · Cited by 25
Yoo, K. J., Johannes, K., Gonzalez, L. E., Patel, A., Shuptrine, C. W., Opheim, Z., Lenz, K. L., Campbell, K., Nguyen, T., Miriyala, J., et al. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2101175 · Cited by 25
Satake, H., Lee, K., Chung, H. C., Lee, J., Yamaguchi, K., Chen, J., Yoshikawa, T., Amagai, K., Yeh, K., Goto, M., et al. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac188 · Cited by 25
Ma, G., Jia, H., Zhang, G., Liang, Y., Dong, X., Fu, G., Wang, X., & Niu, H. (2023) · The Oncologist · doi:10.1093/oncolo/oyad283 · Cited by 25
Prognostic Value of Tumor-Stroma Ratio in Rectal Cancer: A Systematic Review and Meta-analysis
Zhu, Y., Jin, Z., Qian, Y., Shen, Y., & Wang, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.685570 · Cited by 24
Zhao, J., Yu, X., Huang, D., Ma, Z., Gao, B., Cui, J., Chu, Q., Zhou, Q. H., Sun, M., Day, D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006055 · Cited by 24
Molecular and Cellular Requirements for the Assembly of Tertiary Lymphoid Structures
Mueller, C. G., Nayar, S., Campos, J., & Barone, F. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-78127-3_4 · Cited by 23
Jameel, M., & Kwok, H. F. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.011 · Cited by 22
Li, J., Nie, Y., Wu, W., 雷, 鑫., Zhang, T., Mao, Z., Wang, Y., Cao, Z., Tao, K., & Song, W. (2022) · Cancers · doi:10.3390/cancers14205157 · Cited by 21
Vail, K. J., da Silveira, B. P., Bell, S. L., Bordin, A. I., Cohen, N. D., Patrick, K. L., & Watson, R. O. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009888 · Cited by 20
Chiodoni, C., Cancila, V., Renzi, T. A., Perrone, M., Tomirotti, A., Sangaletti, S., Botti, L., Dugo, M., Milani, M., Bongiovanni, L., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1425 · Cited by 19
Wang, B., Hu, J. R., Zhang, J., & Zhao, L. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108646 · Cited by 19
Fortman, D. D., Karunamurthy, A. D., Hartman, D. J., Wang, H., Seigh, L., Abukhiran, I. M., Najjar, Y. G., Pantanowitz, L., Zarour, H. M., Kirkwood, J. M., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae054 · Cited by 19
Berti, F. C. B., Mathias, C., Garcia, L. E., Gradia, D. F., de Araujo‐Souza, P. S., Cipolla, G. A., de Oliveira, J. C., & Malheiros, D. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166172 · Cited by 17
Role of tumor gene mutations in treatment response to immune checkpoint blockades
Wang, M., Liu, Y., Wei, X., & Wei, Y. (2019) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbz006 · Cited by 16
Role of tumor cell pyroptosis in anti-tumor immunotherapy
Zhang, L., Bai, H., Zhou, J., Ye, L., & Gao, L. (2024) · Cell Insight · doi:10.1016/j.cellin.2024.100153 · Cited by 16
Ji, B., Liu, J., Yin, Y., Xu, H. M., Shen, Q., & Yu, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06124-0 · Cited by 15
Gou, M., Zhang, Y., Wang, Z., Qian, N., & Dai, G. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01425-3 · Cited by 15
Identification and characterization of the promoter of cancer-related gene LOXL2
Liu, X., Liu, T., Hu, L., Jiang, T., Liu, H., Wang, S., Lei, Y., Zhu, J., & Bu, Y. (2019) · Experimental Cell Research · doi:10.1016/j.yexcr.2019.111786 · Cited by 12
Science in Focus: The Microbiome and Cancer Therapy
Alexander, J. L., Kohoutová, D., & Powell, N. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.09.004 · Cited by 11
Effect of ubiquitin protease system on DNA damage response in prostate cancer (Review)
Lin, Y., & Jin, X. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12321 · Cited by 10
Xu, W., Yang, J., Ye, S., Liu, W., Lu, J., Anwaier, A., Zhang, H., & Ye, D. (2023) · Immunotherapy · doi:10.2217/imt-2023-0196 · Cited by 10
Küçükköse, E., Baars, M. J. D., Amini, M., Schraa, S. J., Floor, E., Bol, G. M., Rinkes, I. H. M. B., Roodhart, J. M. L., Koopman, M., Laoukili, J., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02500-x · Cited by 9
Targeting FBXO44/SUV39H1 elicits tumor cell-specific DNA replication stress and viral mimicry
Shen, J., & Spruck, C. (2021) · Cell Stress · doi:10.15698/cst2021.03.245 · Cited by 8
Heineman, T. C., Baumgart, M. A., Nanavati, C., Gabrail, N., Wart, S. A. V., Mager, D. E., Maneval, D. C., Fathallah, A. M., & Sekulovich, R. E. (2021) · Clinical and Translational Science · doi:10.1111/cts.13041 · Cited by 8
A Call to Action for Ergonomic Surgical Devices Designed for Diverse Surgeon End Users
Wong, J. M. K., Carey, E. T., King, C. R., Wright, K. N., King, L. P., & Kho, R. M. (2023) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000005068 · Cited by 8
Nanoparticles for Immune Cell Reprogramming and Reengineering of Tumor Microenvironment
Bhise, K., Sau, S., Alzhrani, R. M., & Iyer, A. K. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0203-4_13 · Cited by 5
Epigenetics behind tumor immunology: a mini review
Musella, M., Manduca, N., Maccafeo, E., & Sistigu, A. (2023) · Oncogene · doi:10.1038/s41388-023-02791-7 · Cited by 5
Barteselli, G., Goodman, G. R., Patel, Y., Caro, I., Xue, C., & McCallum, S. (2022) · Drug Safety · doi:10.1007/s40264-022-01248-2 · Cited by 4
Cited by
Lee, C., Kim, M.-J., Kumar, A., Lee, H.-W., Yang, Y., & Kim, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02249-0 · Cited by 365
Gut microbiota dysbiosis induced by brain tumors modulates the efficacy of immunotherapy
Kim, H. C., Kim, H.-J., La, J., Park, W. H., Park, S. H., Kang, B. H., Kim, Y., & Lee, H. K. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115825 · Cited by 23
Metadata
- Authors
- Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-10-18
- Volume
- 9
- Issue
- 1
- Pages
- 274-274
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4403506731
- Cited by
- 682
- References
- 882
- FWCI
- 104.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.